secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001493152-24-041144
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 3.03, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace exchanges all Series B Preferred for Series C Preferred; first step toward Nasdaq uplisting
--------------------------------------------------------------------------------

- All 47,000 Series B Preferred shares (28,000 Ampersand, 19,000 1315 Capital) exchanged for Series C at $1,000 stated value.
- Series C converts at $2.02/share (date closing price), no liquidation preference, no director designation rights, limited protective provisions.
- Series C automatically converts to common upon Nasdaq uplisting; company believes Series C qualifies as stockholders' equity under GAAP.
- Amended investor rights agreement provides registration rights; prior support agreement with 1315 Capital terminated.
- Exchange is first step toward Nasdaq uplisting; no cash received; additional listing requirements may need to be satisfied.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224041144/0001493152-24-041144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315224041144/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-041144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer